Cumberland Pharmaceuticals

CPIX

Market cap $86.9M

CPIX reports positive Phase 2a results for Ifetroban, showing a favorable safety profile and promising early signs of reducing cancer metastasis in high-risk patients.

CPIX launches Vibativ in China through SciClone, expanding access to its antibiotic treatment for serious Gram-positive bacterial infections.

Positive Results from Phase 2a Clinical Trial Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037) Results support development of ifetroban as a candidate for metastasis prevention NASHVILLE, Tenn., June 2, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, and Vanderbilt Health today announce data from a Phase 2a clinical trial of ifetroban to prevent metastasis in high-risk solid tumors.

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib 1 , including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform Opaganib EVD rationale (analogous to EVD treatment pathway): Phase 3 clinical antiviral activity (severe COVID-19) showing 2 : 70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo + SoC (p=0.034)) Improved median time to viral RNA clearance by ≥4 days in opaganib-treated patients (median 10 days vs.

Commercialization in China through partnership with SciClone Pharmaceuticals Expands access to potentially life-saving antibiotic  in the world's second-largest pharmaceutical market NASHVILLE, Tenn., May 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ® (telavancin) injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals (Holdings) Limited.

CPIX posts a wider y//y loss in Q1, as it unveils a $100-million Apotex deal and sharpens focus on orphan drug development.

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2026 Earnings Call Transcript

Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical needs NASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026.

RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies paratuberculosis (MAP)-targeted therapeutic approach for Crohn's disease (CD) In its positive Phase 3 study, RHB-104 met the primary and key secondary endpoints with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone, in treating CD compared to the placebo (standard of care only) group (p = 0.0048) 3 New RHB-204 in vitro data, from both spot and phage assays, demonstrated comparable MAP killing to RHB-1044 . Importantly, MAP killing efficacy was achieved with lower doses of two of the active ingredients compared to RHB-104, indicative of potential for reduced toxicity and side effects Based on the FDA guidance on path to approval, RedHill's novel Phase 2 RHB-204 study is designed to be the first-ever adequately controlled clinical study in a specifically defined MAP-positive CD patient population - a potentially paradigm changing approach to treatment of Crohn's disease.

NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after the market closes on Tuesday, May 5, 2026.